Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. - Wikidata - wikimedia - TriplyDB

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

http://www.wikidata.org/entity/Q33628422

about

Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents The Role of Invariant Natural Killer T Cells in Dendritic Cell Licensing, Cross-Priming, and Memory CD8(+) T Cell Generation NKT cell networks in the regulation of tumor immunity Strategy for Designing a Synthetic Tumor Vaccine: Multi-Component, Multivalency and Antigen Modification The regulatory role of invariant NKT cells in tumor immunity A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates Relationships between Th1 or Th2 iNKT cell activity and structures of CD1d-antigen complexes: meta-analysis of CD1d-glycolipids dynamics simulations Glycolipids that Elicit IFN-γ-Biased Responses from Natural Killer T Cells Enhanced TCR Footprint by a Novel Glycolipid Increases NKT-Dependent Tumor Protection Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells Stimulation of natural killer T cells by glycolipids Regulation of anthrax toxin-specific antibody titers by natural killer T cell-derived IL-4 and IFNγ.Effective cancer vaccine platform based on attenuated salmonella and a type III secretion system Diverse roles of non-diverse molecules: MHC class Ib molecules in host defense and control of autoimmunity Natural killer T cells in advanced melanoma patients treated with tremelimumab Retinoic acid and α-galactosylceramide differentially regulate B cell activation in vitro and augment antibody production in vivo An AAV vector-mediated gene delivery approach facilitates reconstitution of functional human CD8+ T cells in mice Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.Total synthesis of α-1C-galactosylceramide, an immunostimulatory C-glycosphingolipid, and confirmation of the stereochemistry in the first-generation synthesis.Synthesis of C-glycoside analogues of α-galactosylceramide via linear allylic C-H oxidation and allyl cyanate to isocyanate rearrangement.Lipid and Carbohydrate Modifications of α-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation.The Alpha and Omega of Galactosylceramides in T Cell Immune Function.Design, Synthesis, and Immunological Evaluation of Benzyloxyalkyl-Substituted 1,2,3-Triazolyl α-GalCer Analogues.Colocalization of a CD1d-Binding Glycolipid with a Radiation-Attenuated Sporozoite Vaccine in Lymph Node-Resident Dendritic Cells for a Robust Adjuvant Effect.C-Glycosphingolipids with an exo-methylene substituent: stereocontrolled synthesis and immunostimulation of mouse and human natural killer T lymphocytes.Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma.Natural killer T cells in health and disease.Co-administration of α-GalCer analog and TLR4 agonist induces robust CD8(+) T-cell responses to PyCS protein and WT-1 antigen and activates memory-like effector NKT cells Carbohydrates and T cells: a sweet twosome.Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells The role of invariant natural killer T cells in microbial immunity Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens.Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant.iNKT cells in microbial immunity: recognition of microbial glycolipids.Improved outlook on HIV-1 prevention and vaccine development.Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells.Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets.Optimizing NKT cell ligands as vaccine adjuvants Synthesis and biological activities of C-glycosides of KRN 7000 with novel ceramide residues.

P2860

Q26748456-63FE3048-6882-440B-8CD0-8B5E8F591A3B Q26797344-321D5DB2-C03D-439D-8495-D3D58DD65304 Q26866223-100180C0-F06A-40DC-AA09-1D9C8FEB01AE Q27001592-9A4FF6EE-609B-4B04-A851-F1CD57952982 Q27023425-0163A57B-80ED-4067-8DD8-68CF461954F9 Q27303293-92F91D85-46A8-4D1A-BDA3-516A73787136 Q27320844-8AA9BC84-0D51-4B38-AE9E-49CCA4203AC3 Q27676395-5824C853-2EFF-4D2D-A269-933378969961 Q27679771-38F30892-EEFC-487B-B921-F778226CB7CF Q28543248-4FF98F2B-DC0E-49F9-882E-51D986746ADD Q33599059-16555AAE-DC57-4FD2-8CD4-8F66083E1A4B Q34000070-E815E321-290B-4580-A50D-526AA115B651 Q34438443-6EAEFF23-19DA-46FA-A747-FE363457BBA7 Q34626935-6330BAEC-0763-4A55-873F-DA795E3954AB Q35027661-5DF22BE1-4BB4-437E-B671-A48FB7D14BD5 Q35066481-C2912B84-30E7-4ADD-B4A0-90A0ECEF415E Q35091621-64705020-C94C-4B2A-B6C1-27C6CBE64ADD Q35409604-28F88C7C-59EA-49B7-8EF7-D30FC8570F77 Q35476449-DB336224-BB00-4458-A9C5-C9EE84A2309E Q35686895-E5E2CFE8-2726-4542-BA4E-92DB6B4BB985 Q35837120-9C27023A-3DC0-4DB6-9CA8-EBE0F15DEBF5 Q35860595-6DE4DED9-F4E9-4948-B931-F4C917ADEC61 Q35960321-80550204-A8F6-47B4-BBEB-0CC9343DB9C0 Q36031556-F1232FE6-AA42-484B-B672-EE892890583F Q36225616-AF75375E-AD15-4A5F-A886-D10C422D54A0 Q36474450-0BC5A2EA-3147-41D3-9D38-ED568DC34E5B Q36542800-3AABA7E7-EC8B-4A02-88DB-EF30999124BD Q36765720-F746E1C2-A9AD-4958-A00F-35D1D2DD92F4 Q37083610-C401B56D-C0BF-4D40-A8A9-0821B0F04635 Q37118132-A747D80E-4FBE-4C30-BB65-ED94E999E6AC Q37257512-E31F9D92-9E86-4B9A-8D13-E524C30FB59C Q37292523-D372968B-ADA1-413F-997D-D0E1A0C0D027 Q37822744-F8B8941A-5886-4716-A89B-0ED0465F7C2B Q37824065-71C9E527-A497-4B55-A975-C8B4A7AD0114 Q37857337-709ACBFF-9888-434C-8E45-A5E7AAD5561F Q38009870-8C74496F-D745-4B86-B03D-9D2AB0AD402C Q38050484-654E0DBF-48E6-4AE5-A363-A5C82BA7ADEB Q38096489-D74481A4-6B22-47B8-881C-69A6B32D0E60 Q38206819-84C33E56-315F-446E-BF2C-8FA144D7B8C8 Q38862782-F96A5704-448B-40D5-99A5-54F61C69D6E5

P2860

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

http://www.wikidata.org/entity/Q33628422

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

@ast

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

@en

type

label

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

@ast

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

@en

prefLabel

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

@ast

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

@en

P1433

Q33628422-0F7C9060-FA73-484A-8D89-5F03D51B6E01

P1476

Q33628422-4945EA04-8D9D-4BBF-8F7C-CAF6E7E89B10

P2093

Q33628422-2CE0921B-ADDF-4057-9232-C79231CD5174

Q33628422-2E5651D7-96AE-40F8-8C20-369CC8E5CD0C

Q33628422-91874664-D99B-4599-BBAF-9314E69C629C

Q33628422-A609A546-E840-413E-BAFE-0F14BB0CD3D5

Q33628422-B6205A5F-7531-4F03-B594-C518B6D7DCDA

Q33628422-BF153CD9-87A6-4D6E-B954-113CB3B061D8

Q33628422-C74BEB2B-002A-4C58-AC18-95C8F8869D65

P2860

Q33628422-16ED3F27-637E-4828-9108-FBD336A7A948

Q33628422-1B2256E5-7733-4A0C-9FC9-E5DB4AE580B2

Q33628422-2C33B695-8412-4349-A4C2-4800E76DCC16

Q33628422-34C404DF-EFBB-43DE-BF26-6F52623B26BB

Q33628422-38462EAA-1783-4C20-85E5-4BD559735B4E

Q33628422-4077DB74-B8A2-4105-B134-783267698F03

Q33628422-40E3FCBC-31A4-46A5-BEE3-2B59CEC653D1

Q33628422-42EB03B3-63A3-44F7-9BD2-74C0387CFCCC

Q33628422-4B3E03F0-E2EC-42AF-97CD-E81D4152EB24

Q33628422-4C5FF2B6-86A1-4D90-8F5D-A429D36C3F6C

P304

Q33628422-3DF29891-BCFE-4255-B54A-B41CE7A822BC

P31

Q33628422-5164E610-3C62-4DC1-8FEB-6ADE96C89B97

P356

Q33628422-306D5A3B-776F-461C-81C8-858481AFAAA7

P407

Q33628422-A7E8E7C4-DCCC-447F-852B-08F7E8DB0BA9

P433

Q33628422-499F12E3-F777-4694-A41B-2BA62EF85029

P478

Q33628422-D9636A40-4791-43C4-9481-849241EEAD05

P50

Q33628422-F2F909EE-B2DD-4715-9404-C7478577412F

P577

Q33628422-0F0683A9-8D19-4CDB-9942-68F3467A070E

P5875

Q33628422-069116E5-2D5F-4B82-A407-0E4CBCDD1605

P698

Q33628422-0CAF5743-C269-4A7F-B839-E9827078EC61

P921

Q33628422-001EA283-CDC4-45A5-8CE4-ED1F0F41E561

Q33628422-1DD54293-B691-4521-8108-2AB0F50E18ED

Q33628422-39739EDA-5F7A-4801-AB3C-EF2D3798EF00

Q33628422-5B20D4C4-2140-4396-AFC1-EB5FAE79641D

P932

Q33628422-97A96D5D-9FB5-4A38-9357-99B84B722432

P356

PNAS.1006662107

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant.

@en

P2093

Chi-Huey Wong

http://www.w3.org/2001/XMLSchema#string

David D Ho

http://www.w3.org/2001/XMLSchema#string

Douglass Wu

http://www.w3.org/2001/XMLSchema#string

Masakazu Fujio

http://www.w3.org/2001/XMLSchema#string

Masakazu Imamura

http://www.w3.org/2001/XMLSchema#string

Sandhya Vasan

http://www.w3.org/2001/XMLSchema#string

Xiangming Li

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor

Crystal Structures of Mouse CD1d-iGb3 Complex and its Cognate Vα14 T Cell Receptor Suggest a Model for Dual Recognition of Foreign and Self Glycolipids

Structural Evaluation of Potent NKT Cell Agonists: Implications for Design of Novel Stimulatory Ligands

Invariant NKT cells sustain specific B cell responses and memory.

The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells.

Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production

Allergy vaccines--new approaches to an old concept.

Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids.

Toward an understanding of NKT cell biology: progress and paradoxes.

Immunotherapeutic potential for ceramide-based activators of iNKT cells.

P304

13010-13015

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1006662107

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45113613

http://www.w3.org/2001/XMLSchema#string

P698

20616071

http://www.w3.org/2001/XMLSchema#string

P921

alpha-galactosylceramide

1-O-(alpha-D-galactopyranosyl)-N-[11-(4-fluorophenyl)undecanoyl]phytosphingosine

1-O-(alpha-D-galactopyranosyl)-N-(6-phenylhexanoyl)phytosphingosine

1-O-(alpha-D-galactopyranosyl)-N-(8-phenyloctanoyl)phytosphingosine

P932

2919905

http://www.w3.org/2001/XMLSchema#string